WINTON GROUP Ltd Makes New Investment in AbCellera Biologics Inc. $ABCL

WINTON GROUP Ltd acquired a new position in shares of AbCellera Biologics Inc. (NASDAQ:ABCL) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 56,300 shares of the company’s stock, valued at approximately $442,000.

Several other institutional investors also recently modified their holdings of the company. Allworth Financial LP increased its position in shares of AbCellera Biologics by 857.0% during the fourth quarter. Allworth Financial LP now owns 11,274 shares of the company’s stock valued at $39,000 after purchasing an additional 10,096 shares during the period. AssuredPartners Investment Advisors LLC acquired a new stake in AbCellera Biologics during the second quarter worth $80,000. Tradition Wealth Management LLC increased its holdings in AbCellera Biologics by 30.4% in the 4th quarter. Tradition Wealth Management LLC now owns 47,110 shares of the company’s stock valued at $161,000 after buying an additional 10,972 shares during the period. HighTower Advisors LLC increased its holdings in AbCellera Biologics by 12.5% in the 2nd quarter. HighTower Advisors LLC now owns 107,933 shares of the company’s stock valued at $847,000 after buying an additional 12,000 shares during the period. Finally, Janney Montgomery Scott LLC acquired a new position in shares of AbCellera Biologics in the 1st quarter valued at $46,000. Institutional investors and hedge funds own 61.42% of the company’s stock.

AbCellera Biologics Stock Performance

Shares of NASDAQ ABCL opened at $11.41 on Wednesday. AbCellera Biologics Inc. has a 52-week low of $2.74 and a 52-week high of $12.58. The business has a fifty day moving average of $8.88 and a two-hundred day moving average of $6.17. The stock has a market cap of $3.50 billion, a PE ratio of -21.13 and a beta of 1.32.

AbCellera Biologics (NASDAQ:ABCL) last announced its quarterly earnings results on Wednesday, August 5th. The company reported ($0.18) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.16) by ($0.02). The firm had revenue of $4.05 million for the quarter, compared to the consensus estimate of $7.85 million. AbCellera Biologics had a negative net margin of 248.83% and a negative return on equity of 17.49%. Analysts predict that AbCellera Biologics Inc. will post -0.68 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on ABCL shares. Stifel Nicolaus lifted their target price on shares of AbCellera Biologics from $8.00 to $9.00 and gave the company a “buy” rating in a research report on Thursday, August 6th. Cantor Fitzgerald increased their price target on shares of AbCellera Biologics from $11.00 to $12.00 and gave the stock an “overweight” rating in a research report on Thursday, August 6th. Weiss Ratings restated a “sell (d-)” rating on shares of AbCellera Biologics in a research note on Friday, July 17th. Truist Financial lifted their price objective on AbCellera Biologics from $12.00 to $30.00 and gave the company a “buy” rating in a report on Tuesday, August 11th. Finally, Wall Street Zen upgraded AbCellera Biologics from a “sell” rating to a “hold” rating in a research note on Saturday, September 5th. One equities research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, AbCellera Biologics currently has a consensus rating of “Moderate Buy” and an average price target of $12.83.

About AbCellera Biologics

AbCellera Biologics Inc is a biotechnology company that develops antibody-based medicines in partnership with pharmaceutical and biotechnology companies. Its technology platform combines artificial intelligence, machine learning, high-throughput screening, single-cell analysis and other laboratory techniques to identify and evaluate antibody candidates.

The company provides integrated antibody discovery and development services, helping partners move from biological targets and immune-cell samples to optimized therapeutic antibody candidates.